SlideShare a Scribd company logo
1 of 20
Why I Fight to Improve the FDA, and
          You Should Too

    Diana Zuckerman, PhD, President
National Research Center for Women & Families
    Cancer Prevention and Treatment Fund
Unsafe Medical Products
       in the News


Medtronic Agrees to                     With Warning, a
$23.5 Million Settlement
in Kickback Case                        Hip Device Is
                     Trial of Synthetic  Withdrawn
                    Mesh in Pelvic
                    Surgery Ends Early
Defective Medical Devices
     Hit Prime Time
Low Risk Devices
Moderate Risk (510k)
95+% are Reviewed as 510(k)
IOM: No evidence of safety or efficacy
Must be Substantially Equivalent to
  “predicate device or devices”

 No clinical trials
 No inspections
 No studies are required post-market
 Can’t be rescinded
High Risk Medical Devices
(pacemaker, heart, infusion pump)
Highest Risk Devices: PMA
Premarket Approval
 Reasonably Safe
 Reasonably Effective




Based on one clinical trial (not double
 blind ) with smaller sample than
 required for prescription drug data
FDA Approval of
         Drugs and Devices
              Does NOT mean

 Nobody will die or be harmed
 This product is safe for long-termuse
 This product is more effective than other
  products on the market
510k Substantial Equivalence
 Similar “intended use”
 Similar material or mechanism of
  action
 Similar risk: benefit ratio
Are these substantially
              equivalent?




                              =
                              ?
Vitek (teflon) TMJ implants       Dow silicone sheet
Are these substantially
      equivalent?




         =
         ?
GAO Report
  510(k) Reviews in 2003-2007

 FDA Cleared 90% of 13,000+
 medical devices
More Recalls
     Almost  half a billion 510(k) devices were
     recalled as high risk in late 2010 and
     early 2011, including contaminated
     alcohol swabs that killed this 2-year old
     boy and then infected others.



1
More Recalls
     GAO’s estimates that 3,000+ recalls from
     2005 through 2009 were high-risk or
     moderate-risk recalls

     Divide 3000 by the device industry’s
     estimate of 20,000 device submissions.


1
     RESULTS: 15% were recalled!
Deaths reported on FDA web site

     4,556 deaths for medical devices in
     2009 (increased 60% compared to
     2006).


1
Improving Safety

 Clinical trials

 Inspections

 Any flaws can be caught   sooner with
  post-market studies, registries,
  surveillance
Conclusions
 Can’t have evidence-based medicine
 with no evidence

 IOM says that over 95% of new   medical
 devices have no clinical trials and are
 not proven safe or effective

 Clinical trials are
                   less stringent for
 devices than for prescription drugs
Consumers Should Care


 Half billion
             510(k) devices were recently
 recalled as high risk

 Approx 15% of regulated devices    are
 recalled as high or moderate risk
Diana Zuckerman, PhD
            President
National Research Center for Women &
               Families
Cancer Prevention and Treatment Fund
      www.center4research.org
      www.stopcancerfund.org

More Related Content

What's hot

Pharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLSPharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLSKatalyst HLS
 
Searching literature databases for post authorisation safety studies (pass)
Searching literature databases for post authorisation safety studies (pass)Searching literature databases for post authorisation safety studies (pass)
Searching literature databases for post authorisation safety studies (pass)Ann-Marie Roche
 
Improving Patient Safety, Inventory Management, Quality and Cost Savings via ...
Improving Patient Safety, Inventory Management, Quality and Cost Savings via ...Improving Patient Safety, Inventory Management, Quality and Cost Savings via ...
Improving Patient Safety, Inventory Management, Quality and Cost Savings via ...Charles J. DiComo, PhD
 
Crani with YouTube
Crani with YouTubeCrani with YouTube
Crani with YouTubeLenojone
 
Crani with audio
Crani with audioCrani with audio
Crani with audioLenojone
 
Croup clinical features, evaluation, and diagnosis
Croup  clinical features, evaluation, and diagnosisCroup  clinical features, evaluation, and diagnosis
Croup clinical features, evaluation, and diagnosisMartin Romero Torres
 
Processing Hereditary Cancer Panels in VarSeq
Processing Hereditary Cancer Panels in VarSeqProcessing Hereditary Cancer Panels in VarSeq
Processing Hereditary Cancer Panels in VarSeqGolden Helix
 
The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...Arete-Zoe, LLC
 
Argus Patient Screen Tab Training - Katalyst HLS
Argus Patient Screen Tab Training - Katalyst HLSArgus Patient Screen Tab Training - Katalyst HLS
Argus Patient Screen Tab Training - Katalyst HLSKatalyst HLS
 
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...Golden Helix
 
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCEAN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCERamakrishna K
 
Argus Product Tab Screens - Katalyst HLS
Argus Product Tab Screens - Katalyst HLSArgus Product Tab Screens - Katalyst HLS
Argus Product Tab Screens - Katalyst HLSKatalyst HLS
 
ICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSKatalyst HLS
 
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB UpdatesReduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB UpdatesGolden Helix
 
Family-Based Workflows in VarSeq and VSClinical
Family-Based Workflows in VarSeq and VSClinicalFamily-Based Workflows in VarSeq and VSClinical
Family-Based Workflows in VarSeq and VSClinicalGolden Helix
 
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...Hivlife Info
 
Cellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic PlatformCellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic PlatformLavance L. Northington
 
Kuldev Singh, MD, PhD
Kuldev Singh, MD, PhDKuldev Singh, MD, PhD
Kuldev Singh, MD, PhDHealthegy
 

What's hot (20)

Pharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLSPharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLS
 
Searching literature databases for post authorisation safety studies (pass)
Searching literature databases for post authorisation safety studies (pass)Searching literature databases for post authorisation safety studies (pass)
Searching literature databases for post authorisation safety studies (pass)
 
Improving Patient Safety, Inventory Management, Quality and Cost Savings via ...
Improving Patient Safety, Inventory Management, Quality and Cost Savings via ...Improving Patient Safety, Inventory Management, Quality and Cost Savings via ...
Improving Patient Safety, Inventory Management, Quality and Cost Savings via ...
 
Crani with YouTube
Crani with YouTubeCrani with YouTube
Crani with YouTube
 
Crani with audio
Crani with audioCrani with audio
Crani with audio
 
Croup clinical features, evaluation, and diagnosis
Croup  clinical features, evaluation, and diagnosisCroup  clinical features, evaluation, and diagnosis
Croup clinical features, evaluation, and diagnosis
 
Processing Hereditary Cancer Panels in VarSeq
Processing Hereditary Cancer Panels in VarSeqProcessing Hereditary Cancer Panels in VarSeq
Processing Hereditary Cancer Panels in VarSeq
 
The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...
 
Argus Patient Screen Tab Training - Katalyst HLS
Argus Patient Screen Tab Training - Katalyst HLSArgus Patient Screen Tab Training - Katalyst HLS
Argus Patient Screen Tab Training - Katalyst HLS
 
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
 
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCEAN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCE
 
PMED: APPM Workshop: Personalized Patient Vital Sign Monitoring in Home, Hosp...
PMED: APPM Workshop: Personalized Patient Vital Sign Monitoring in Home, Hosp...PMED: APPM Workshop: Personalized Patient Vital Sign Monitoring in Home, Hosp...
PMED: APPM Workshop: Personalized Patient Vital Sign Monitoring in Home, Hosp...
 
Argus Product Tab Screens - Katalyst HLS
Argus Product Tab Screens - Katalyst HLSArgus Product Tab Screens - Katalyst HLS
Argus Product Tab Screens - Katalyst HLS
 
ICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLS
 
MDC Connects: Making Safety Part of Drug Design
MDC Connects: Making Safety Part of Drug DesignMDC Connects: Making Safety Part of Drug Design
MDC Connects: Making Safety Part of Drug Design
 
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB UpdatesReduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
Reduce Turn-Around with Enhanced Cancer Annotations and CancerKB Updates
 
Family-Based Workflows in VarSeq and VSClinical
Family-Based Workflows in VarSeq and VSClinicalFamily-Based Workflows in VarSeq and VSClinical
Family-Based Workflows in VarSeq and VSClinical
 
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
 
Cellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic PlatformCellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic Platform
 
Kuldev Singh, MD, PhD
Kuldev Singh, MD, PhDKuldev Singh, MD, PhD
Kuldev Singh, MD, PhD
 

Viewers also liked (10)

Ryan cue consumer perspective
Ryan cue consumer perspectiveRyan cue consumer perspective
Ryan cue consumer perspective
 
Panel1
Panel1Panel1
Panel1
 
Johnson, lorraine cue 6.4.12 final final
Johnson, lorraine   cue 6.4.12 final finalJohnson, lorraine   cue 6.4.12 final final
Johnson, lorraine cue 6.4.12 final final
 
Panel3
Panel3Panel3
Panel3
 
Frank cue 08_june2012v4
Frank cue 08_june2012v4Frank cue 08_june2012v4
Frank cue 08_june2012v4
 
Gunnppt
GunnpptGunnppt
Gunnppt
 
Panel2
Panel2Panel2
Panel2
 
Norsigianppt
NorsigianpptNorsigianppt
Norsigianppt
 
Mullins 2012 05_30
Mullins 2012 05_30Mullins 2012 05_30
Mullins 2012 05_30
 
Slutsky 2012 CUE Annual Meeting
Slutsky 2012 CUE Annual MeetingSlutsky 2012 CUE Annual Meeting
Slutsky 2012 CUE Annual Meeting
 

Similar to Zuckerman cue june 2012

8. medical device manufacturing breakout session
8. medical device manufacturing breakout session8. medical device manufacturing breakout session
8. medical device manufacturing breakout sessionGreaterRomeChamber
 
Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history EstelaJeffery653
 
Working the Science and Regulations Harder to Win Your Drug and Device Cases
Working the Science and Regulations Harder to Win Your Drug and Device CasesWorking the Science and Regulations Harder to Win Your Drug and Device Cases
Working the Science and Regulations Harder to Win Your Drug and Device CasesSara Dunlap
 
AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101AnitaBell
 
Identifying Safety Signals in Pharmaceutical Product Development
Identifying Safety Signals in Pharmaceutical Product DevelopmentIdentifying Safety Signals in Pharmaceutical Product Development
Identifying Safety Signals in Pharmaceutical Product DevelopmentBrook White, PMP
 
Different Stages of Medical Device Development and Drug Development: PepgraDi...
Different Stages of Medical Device Development and Drug Development: PepgraDi...Different Stages of Medical Device Development and Drug Development: PepgraDi...
Different Stages of Medical Device Development and Drug Development: PepgraDi...PEPGRA Healthcare
 
Medical device regulation
Medical device regulationMedical device regulation
Medical device regulationCarlo Favaretti
 
Medical Device FDA Regulations and Classifications infographic
Medical Device FDA Regulations and Classifications infographicMedical Device FDA Regulations and Classifications infographic
Medical Device FDA Regulations and Classifications infographicKathleen Murray
 
FDA classify Medical Devices and how to report device problems A Systematic R...
FDA classify Medical Devices and how to report device problems A Systematic R...FDA classify Medical Devices and how to report device problems A Systematic R...
FDA classify Medical Devices and how to report device problems A Systematic R...Pubrica
 
FDA classify Medical Devices and how to report device problems A Systematic R...
FDA classify Medical Devices and how to report device problems A Systematic R...FDA classify Medical Devices and how to report device problems A Systematic R...
FDA classify Medical Devices and how to report device problems A Systematic R...Pubrica
 
Pv day frankfurt june 2015 zittartz presentation
Pv day frankfurt june 2015 zittartz presentationPv day frankfurt june 2015 zittartz presentation
Pv day frankfurt june 2015 zittartz presentationpharmasol
 
Introduction to Regulatory Affairs - Pauwels Consulting Academy
Introduction to Regulatory Affairs  - Pauwels Consulting AcademyIntroduction to Regulatory Affairs  - Pauwels Consulting Academy
Introduction to Regulatory Affairs - Pauwels Consulting AcademyPauwels Consulting
 
Patient Safety in Clinical Trials
Patient Safety in Clinical TrialsPatient Safety in Clinical Trials
Patient Safety in Clinical TrialsMedelis
 
Oct2019 presentation tim grammer 13 feb2019
Oct2019 presentation tim grammer 13 feb2019Oct2019 presentation tim grammer 13 feb2019
Oct2019 presentation tim grammer 13 feb2019Timothy Grammer
 
Pharmaceutical Regulaions; Emergence & Complexity
Pharmaceutical Regulaions; Emergence & ComplexityPharmaceutical Regulaions; Emergence & Complexity
Pharmaceutical Regulaions; Emergence & ComplexityObaid Ali / Roohi B. Obaid
 

Similar to Zuckerman cue june 2012 (20)

8. medical device manufacturing breakout session
8. medical device manufacturing breakout session8. medical device manufacturing breakout session
8. medical device manufacturing breakout session
 
Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history
 
Working the Science and Regulations Harder to Win Your Drug and Device Cases
Working the Science and Regulations Harder to Win Your Drug and Device CasesWorking the Science and Regulations Harder to Win Your Drug and Device Cases
Working the Science and Regulations Harder to Win Your Drug and Device Cases
 
AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101AzCI presents: FDA Drug Development 101
AzCI presents: FDA Drug Development 101
 
Identifying Safety Signals in Pharmaceutical Product Development
Identifying Safety Signals in Pharmaceutical Product DevelopmentIdentifying Safety Signals in Pharmaceutical Product Development
Identifying Safety Signals in Pharmaceutical Product Development
 
Different Stages of Medical Device Development and Drug Development: PepgraDi...
Different Stages of Medical Device Development and Drug Development: PepgraDi...Different Stages of Medical Device Development and Drug Development: PepgraDi...
Different Stages of Medical Device Development and Drug Development: PepgraDi...
 
Medical device regulation
Medical device regulationMedical device regulation
Medical device regulation
 
Medical Device FDA Regulations and Classifications infographic
Medical Device FDA Regulations and Classifications infographicMedical Device FDA Regulations and Classifications infographic
Medical Device FDA Regulations and Classifications infographic
 
FDA classify Medical Devices and how to report device problems A Systematic R...
FDA classify Medical Devices and how to report device problems A Systematic R...FDA classify Medical Devices and how to report device problems A Systematic R...
FDA classify Medical Devices and how to report device problems A Systematic R...
 
Akhu Therapeutics Pitch Deck
Akhu Therapeutics Pitch DeckAkhu Therapeutics Pitch Deck
Akhu Therapeutics Pitch Deck
 
FDA classify Medical Devices and how to report device problems A Systematic R...
FDA classify Medical Devices and how to report device problems A Systematic R...FDA classify Medical Devices and how to report device problems A Systematic R...
FDA classify Medical Devices and how to report device problems A Systematic R...
 
Making medicines safer_-_express_pharma
Making medicines safer_-_express_pharmaMaking medicines safer_-_express_pharma
Making medicines safer_-_express_pharma
 
Pv day frankfurt june 2015 zittartz presentation
Pv day frankfurt june 2015 zittartz presentationPv day frankfurt june 2015 zittartz presentation
Pv day frankfurt june 2015 zittartz presentation
 
Introduction to Regulatory Affairs - Pauwels Consulting Academy
Introduction to Regulatory Affairs  - Pauwels Consulting AcademyIntroduction to Regulatory Affairs  - Pauwels Consulting Academy
Introduction to Regulatory Affairs - Pauwels Consulting Academy
 
Patient Safety in Clinical Trials
Patient Safety in Clinical TrialsPatient Safety in Clinical Trials
Patient Safety in Clinical Trials
 
Vaccine101, Dynport Vaccine Company LLC
Vaccine101, Dynport Vaccine Company LLCVaccine101, Dynport Vaccine Company LLC
Vaccine101, Dynport Vaccine Company LLC
 
Oct2019 presentation tim grammer 13 feb2019
Oct2019 presentation tim grammer 13 feb2019Oct2019 presentation tim grammer 13 feb2019
Oct2019 presentation tim grammer 13 feb2019
 
Medical devices
Medical devicesMedical devices
Medical devices
 
Vaccine Development
Vaccine DevelopmentVaccine Development
Vaccine Development
 
Pharmaceutical Regulaions; Emergence & Complexity
Pharmaceutical Regulaions; Emergence & ComplexityPharmaceutical Regulaions; Emergence & Complexity
Pharmaceutical Regulaions; Emergence & Complexity
 

More from CUE - Consumers United for Evidence-based Healthcare

More from CUE - Consumers United for Evidence-based Healthcare (20)

Panel: Where Do We Get Our Info?- Q&A
Panel: Where Do We Get Our Info?- Q&APanel: Where Do We Get Our Info?- Q&A
Panel: Where Do We Get Our Info?- Q&A
 
What's New in CUE- Nancy Fitton
What's New in CUE- Nancy FittonWhat's New in CUE- Nancy Fitton
What's New in CUE- Nancy Fitton
 
Panel: CUE in Partnership- Marguerite Koster
Panel: CUE in Partnership- Marguerite KosterPanel: CUE in Partnership- Marguerite Koster
Panel: CUE in Partnership- Marguerite Koster
 
Welcoming remarks: Lorraine Johnson
Welcoming remarks: Lorraine JohnsonWelcoming remarks: Lorraine Johnson
Welcoming remarks: Lorraine Johnson
 
Panel: Open Access- Kate Ryan
Panel: Open Access- Kate RyanPanel: Open Access- Kate Ryan
Panel: Open Access- Kate Ryan
 
Panel: Open Access- Steven Salzberg
Panel: Open Access- Steven SalzbergPanel: Open Access- Steven Salzberg
Panel: Open Access- Steven Salzberg
 
Panel: Open Access to Data- Q&A
Panel: Open Access to Data- Q&APanel: Open Access to Data- Q&A
Panel: Open Access to Data- Q&A
 
Panel: PCORI- Q&A
Panel: PCORI- Q&APanel: PCORI- Q&A
Panel: PCORI- Q&A
 
Panel: Where Do We Get Information?- Sally Okun
Panel: Where Do We Get Information?- Sally OkunPanel: Where Do We Get Information?- Sally Okun
Panel: Where Do We Get Information?- Sally Okun
 
How to Survive a Plague- Tim Horn
How to Survive a Plague- Tim HornHow to Survive a Plague- Tim Horn
How to Survive a Plague- Tim Horn
 
Panel: Open Access- Peter Doshi
Panel: Open Access- Peter DoshiPanel: Open Access- Peter Doshi
Panel: Open Access- Peter Doshi
 
Panel: Where Do We Get Information?- Carol Sakala
Panel: Where Do We Get Information?- Carol SakalaPanel: Where Do We Get Information?- Carol Sakala
Panel: Where Do We Get Information?- Carol Sakala
 
CUE's 10th Anniversary- Kay Dickersin
CUE's 10th Anniversary- Kay DickersinCUE's 10th Anniversary- Kay Dickersin
CUE's 10th Anniversary- Kay Dickersin
 
Panel: CUE in partnership- John Santa
Panel: CUE in partnership- John SantaPanel: CUE in partnership- John Santa
Panel: CUE in partnership- John Santa
 
Welcoming Remarks: Rebecca Burkholder
Welcoming Remarks: Rebecca BurkholderWelcoming Remarks: Rebecca Burkholder
Welcoming Remarks: Rebecca Burkholder
 
Panel: PCORI- Ann Fonfa
Panel: PCORI- Ann FonfaPanel: PCORI- Ann Fonfa
Panel: PCORI- Ann Fonfa
 
Panel: PCORI- Claire Snyder
Panel: PCORI- Claire SnyderPanel: PCORI- Claire Snyder
Panel: PCORI- Claire Snyder
 
Panel: PCORI- Jim Hulbert
Panel: PCORI- Jim HulbertPanel: PCORI- Jim Hulbert
Panel: PCORI- Jim Hulbert
 
Panel: PCORI- Sue Sheridan
Panel: PCORI- Sue SheridanPanel: PCORI- Sue Sheridan
Panel: PCORI- Sue Sheridan
 
Panel Q&A: CUE in Partnership
Panel Q&A: CUE in PartnershipPanel Q&A: CUE in Partnership
Panel Q&A: CUE in Partnership
 

Recently uploaded

Future Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionFuture Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionMintel Group
 
Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Kirill Klimov
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCRashishs7044
 
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfDigital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfJos Voskuil
 
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort ServiceCall US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Servicecallgirls2057
 
IoT Insurance Observatory: summary 2024
IoT Insurance Observatory:  summary 2024IoT Insurance Observatory:  summary 2024
IoT Insurance Observatory: summary 2024Matteo Carbone
 
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdfNewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdfKhaled Al Awadi
 
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu MenzaYouth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menzaictsugar
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMVoces Mineras
 
MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?Olivia Kresic
 
Kenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith PereraKenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith Pereraictsugar
 
India Consumer 2024 Redacted Sample Report
India Consumer 2024 Redacted Sample ReportIndia Consumer 2024 Redacted Sample Report
India Consumer 2024 Redacted Sample ReportMintel Group
 
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxContemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxMarkAnthonyAurellano
 
PSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationPSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationAnamaria Contreras
 
Islamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in IslamabadIslamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in IslamabadAyesha Khan
 
Organizational Structure Running A Successful Business
Organizational Structure Running A Successful BusinessOrganizational Structure Running A Successful Business
Organizational Structure Running A Successful BusinessSeta Wicaksana
 
International Business Environments and Operations 16th Global Edition test b...
International Business Environments and Operations 16th Global Edition test b...International Business Environments and Operations 16th Global Edition test b...
International Business Environments and Operations 16th Global Edition test b...ssuserf63bd7
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMintel Group
 
8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCR8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCRashishs7044
 

Recently uploaded (20)

Future Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionFuture Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted Version
 
Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024
 
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
8447779800, Low rate Call girls in Kotla Mubarakpur Delhi NCR
 
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfDigital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdf
 
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort ServiceCall US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
Call US-88OO1O2216 Call Girls In Mahipalpur Female Escort Service
 
IoT Insurance Observatory: summary 2024
IoT Insurance Observatory:  summary 2024IoT Insurance Observatory:  summary 2024
IoT Insurance Observatory: summary 2024
 
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdfNewBase  19 April  2024  Energy News issue - 1717 by Khaled Al Awadi.pdf
NewBase 19 April 2024 Energy News issue - 1717 by Khaled Al Awadi.pdf
 
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu MenzaYouth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
Youth Involvement in an Innovative Coconut Value Chain by Mwalimu Menza
 
Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQM
 
MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?
 
Kenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith PereraKenya Coconut Production Presentation by Dr. Lalith Perera
Kenya Coconut Production Presentation by Dr. Lalith Perera
 
India Consumer 2024 Redacted Sample Report
India Consumer 2024 Redacted Sample ReportIndia Consumer 2024 Redacted Sample Report
India Consumer 2024 Redacted Sample Report
 
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptxContemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
Contemporary Economic Issues Facing the Filipino Entrepreneur (1).pptx
 
PSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationPSCC - Capability Statement Presentation
PSCC - Capability Statement Presentation
 
Islamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in IslamabadIslamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in Islamabad
 
Organizational Structure Running A Successful Business
Organizational Structure Running A Successful BusinessOrganizational Structure Running A Successful Business
Organizational Structure Running A Successful Business
 
Call Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North GoaCall Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North Goa
 
International Business Environments and Operations 16th Global Edition test b...
International Business Environments and Operations 16th Global Edition test b...International Business Environments and Operations 16th Global Edition test b...
International Business Environments and Operations 16th Global Edition test b...
 
Market Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 EditionMarket Sizes Sample Report - 2024 Edition
Market Sizes Sample Report - 2024 Edition
 
8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCR8447779800, Low rate Call girls in Tughlakabad Delhi NCR
8447779800, Low rate Call girls in Tughlakabad Delhi NCR
 

Zuckerman cue june 2012

  • 1. Why I Fight to Improve the FDA, and You Should Too Diana Zuckerman, PhD, President National Research Center for Women & Families Cancer Prevention and Treatment Fund
  • 2. Unsafe Medical Products in the News Medtronic Agrees to With Warning, a $23.5 Million Settlement in Kickback Case Hip Device Is Trial of Synthetic Withdrawn Mesh in Pelvic Surgery Ends Early
  • 3. Defective Medical Devices Hit Prime Time
  • 6. 95+% are Reviewed as 510(k) IOM: No evidence of safety or efficacy Must be Substantially Equivalent to “predicate device or devices”  No clinical trials  No inspections  No studies are required post-market  Can’t be rescinded
  • 7. High Risk Medical Devices (pacemaker, heart, infusion pump)
  • 8. Highest Risk Devices: PMA Premarket Approval  Reasonably Safe  Reasonably Effective Based on one clinical trial (not double blind ) with smaller sample than required for prescription drug data
  • 9. FDA Approval of Drugs and Devices Does NOT mean  Nobody will die or be harmed  This product is safe for long-termuse  This product is more effective than other products on the market
  • 10. 510k Substantial Equivalence  Similar “intended use”  Similar material or mechanism of action  Similar risk: benefit ratio
  • 11. Are these substantially equivalent? = ? Vitek (teflon) TMJ implants Dow silicone sheet
  • 12. Are these substantially equivalent? = ?
  • 13. GAO Report 510(k) Reviews in 2003-2007  FDA Cleared 90% of 13,000+ medical devices
  • 14. More Recalls  Almost half a billion 510(k) devices were recalled as high risk in late 2010 and early 2011, including contaminated alcohol swabs that killed this 2-year old boy and then infected others. 1
  • 15. More Recalls  GAO’s estimates that 3,000+ recalls from 2005 through 2009 were high-risk or moderate-risk recalls  Divide 3000 by the device industry’s estimate of 20,000 device submissions. 1  RESULTS: 15% were recalled!
  • 16. Deaths reported on FDA web site  4,556 deaths for medical devices in 2009 (increased 60% compared to 2006). 1
  • 17. Improving Safety  Clinical trials  Inspections  Any flaws can be caught sooner with post-market studies, registries, surveillance
  • 18. Conclusions  Can’t have evidence-based medicine with no evidence  IOM says that over 95% of new medical devices have no clinical trials and are not proven safe or effective  Clinical trials are less stringent for devices than for prescription drugs
  • 19. Consumers Should Care  Half billion 510(k) devices were recently recalled as high risk  Approx 15% of regulated devices are recalled as high or moderate risk
  • 20. Diana Zuckerman, PhD President National Research Center for Women & Families Cancer Prevention and Treatment Fund www.center4research.org www.stopcancerfund.org